The Anti‐Androgen Hydroxyflutamide and Androgens Inhibit Interleukin‐6 Production by an Androgen‐Responsive Human Osteoblastic Cell Line
- 1 August 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 14 (8) , 1330-1337
- https://doi.org/10.1359/jbmr.1999.14.8.1330
Abstract
While androgens clearly have significant skeletal effects, the paracrine mediators of androgen action on bone are at present unclear. Interleukin-6 (IL-6) is a candidate cytokine that is produced by osteoblastic lineage cells and promotes osteoclastogenesis and bone resorption. Here, we assessed constitutive as well as IL-1beta- and tumor necrosis factor-alpha (TNF-alpha)-stimulated IL-6 mRNA expression by Northern analysis and protein secretion by immunoassay in a human androgen-responsive osteoblastic cell line (hFOB/AR-6) which contains approximately 4000 androgen receptors (ARs)/nucleus. Treatment with 5alpha-dihydrotestosterone (DHT) dose-dependently inhibited constitutive and TNF-alpha/IL-1beta-stimulated IL-6 mRNA steady-state levels in hFOB/AR-6 cells by 70-80% at 10-7 M. In addition, testosterone also suppressed TNF-alpha/IL-1beta-stimulated IL-6 mRNA levels by 57%, while the adrenal androgen dehydroepiandrosterone had no effect. Of note, the specific AR antagonist, hydroxyflutamide, also inhibited IL-6 mRNA levels by 70%. Consistent with the Northern analyses, treatment with 5alpha-DHT, testosterone, and hydroxyflutamide also inhibited IL-6 protein production by 79%, 62%, and 71%, respectively (p < 0.001), while these agents had no effect on IL-6 soluble receptor levels. Finally, we demonstrated that hydroxyflutamide treatment of hFOB/AR-6 cells markedly inhibited the activation and binding of NF-kappaB (a known stimulator of IL-6 gene transcription) to its response element, thus providing a potential mechanism for its effect on IL-6 production by osteoblasts. These data are consistent with the hypothesis that suppression of osteoblast IL-6 production by androgens may mediate, at least in part, the antiresorptive effects of androgens on bone. Moreover, our findings also indicate that hydroxyflutamide, which is a known AR antagonist in most tissues, may function as a selective AR modulator for effects on IL-6 production by osteoblasts.Keywords
This publication has 39 references indexed in Scilit:
- Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell lineJournal of Cellular Biochemistry, 1998
- Bisphosphonates inhibit IL-6 production by human osteoblast-like cellsScandinavian Journal of Rheumatology, 1998
- Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in boneOsteoporosis International, 1997
- Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptorsJournal of Bone and Mineral Research, 1996
- Skeletal effects of estrogenEndocrine Reviews, 1994
- 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.Journal of Clinical Investigation, 1994
- Flutamide-mediated androgen blockade evokes osteopenia in the female ratJournal of Bone and Mineral Research, 1993
- Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6Science, 1992
- RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexaminationBiochemistry, 1977
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976